Generic Name and Formulations:
Mesna 400mg; tabs.
Indications for MESNEX:
Prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
See literature. IV Schedule: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide; total daily dose is 60% the ifosfamide dose. IV and oral dosing: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration, followed by the tablets given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide; total daily dose is 100% of the ifosfamide dose. Repeat schedule on each day ifosfamide is given. If vomiting occurs within 2hrs of oral mesna, repeat dose or give IV mesna.
Hypersensitivity to thiol compounds.
Monitor morning specimen of urine for the presence of hematuria each day prior to ifosfamide therapy; consider dose reduction or discontinue if hematuria occurs. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
GI upset, fever, anorexia, flatulence, constipation, rhinitis, rigors, back pain, rash, conjunctivitis, arthralgia, headache, inj site reactions, flushing, dizziness, pharyngitis, hyperaesthesia, flu-like symptoms, coughing; hypersensitivity reactions.
Patients taking mesna should drink at least a quart of liquid a day.
Tabs—10; Multidose vials—1, 10
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)